Jump to Main Contents
Institute for Cancer Control

Home > Divisions & Departments > Division of Biostatistical Research > Publications

Publications

2022

Jurnal

  1. Nakamura K, Ozawa H, Shibata T, Ushirozawa N, Hata T, Okita N, Fuse N, Sato N, Ikeda K, Hanaoka H, Maruyama T, Wada M, Shimizu S, Kasai H, Yamamoto Y, Sakurai J, Todaka K, Tashiro S, Yamamoto H. Survey Results and Recommendations from Japanese Stakeholders for Good Clinical Practice Renovation. Ther Innov Regul Sci. 2022 56(2):220-229.
  2. Ohba A, Morizane C, Ueno M, Kobayashi S, Kawamoto Y, Komatsu Y, Ikeda M, Sasaki M, Okano N, Furuse J, Hiraoka N, Yoshida H, Kuchiba A, Sadachi R, Nakamura K, Matsui N, Nakamura Y, Okamoto W, Yoshino T, Okusaka T.Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. Future Oncol. 2022 18(19):2351-2360.
  3. Takahashi K, Yamamoto K, Kuchiba A, Koyama T. Confidence interval for micro-averaged F1 and macro-averaged F1 scores. Appl Intell. 2022 52: 4961–4972.
  4. Kikuchi K, Yamazaki N, Nozawa K, Fukuda H, Shibata T, Machida R, Hamaguchi T, Takashima A, Shoji H, Boku N, Takatsuka S, Takenouchi T, Nishina T, Yoshikawa S, Takahashi M, Hasegawa A, Kawazoe A, Masuishi T, Mizutani H, Kiyohara Y. Topical corticosteroid therapy for facial acneiform eruption due to EGFR inhibitors in metastatic colorectal cancer patients: a randomized controlled trial comparing starting with a very strong or a weak topical corticosteroid (FAEISS study, NCCH1512, colorectal part). Support Care Cancer. 2022 30(5):4497-4504.
  5. Tsuji K, Matsuoka YJ, Kuchiba A, Suto A, Ochi E. Accuracy of exercise-based tests for estimating cardiorespiratory fitness and muscle strength in breast cancer survivors in Japan. Supportive Care in Cancer 2022 30(5):3857-3863.
  6. Tsukamoto S, Kuchiba A, Moritani K, Shida D, Katayama H, Yorikane E,Kanemitsu Y. Laparoscopic surgery using 8 K ultra-high-definition technology: Outcomes of a phase II study. Asian J Endosc Surg. 2022 15(1):7-14.
  7. Shimizu Y, Tsuji K, Ochi E, Okubo R, Kuchiba A, Shimazu T, Tatematsu N, Sakurai N, Iwata H, Matsuoka Y. Oncology care providers’ awareness and practice related to physical activity promotion for breast cancer survivors and barriers and facilitators to such promotion: A nationwide cross-sectional web-based survey. Supportive Care in Cancer 2022 30(4):3105-3118.
  8. Oshima K, Kato K, Ito Y, Daiko H, Nozaki I, Nakagawa S, Shibuya Y, Kojima T, Toh Y, Okada M, Hironaka S, Akiyama Y, Komatsu Y, Maejima K, Nakagawa H, Onuki  R, Nagai M, Kato M, Kanato K, Kuchiba A, Nakamura K, Kitagawa Y. A prognostic biomarker study in patients with clinical stage I esophageal squamous cell carcinoma: JCOG0502-A1. Cancer Science 2022 113(3):1018-1027.

2021

Jurnal

  1. Yuwaki K, Kuchiba A, Otsuki A, Odawara M, Okuhara T, Ishikawa H, Inoue M, Tsugane S, Shimazu T. Effectiveness of a cancer risk prediction tool on lifestyle habits: a randomized controlled trial. Cancer Epidemiology, Biomarkers & Prevention. 2021 30(6):1063-71.
  2. Okuma HS, Yonemori K, Kojima Y, Tanioka M, Sudo K, Noguchi E, Hijioka S, Wakakuwa K, Kato K, Hirakawa A, Kuchiba A, Kubo T, Ichikawa H, Yoshida A, Yatabe Y, Nakamura K, Mano H, Yamamoto N, Yasuhiro F. Clinical utility of circulating tumor DNA profiling in advanced rare cancers. Frontiers in Oncology 2021 11:732525.
  3. Shimomura A, Tamura K, Tanaka K, Mizutani T, Sasaki K, Sekino Y, Sawaki M, Shien T, Shibata T, Iwata H. A randomized phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: Japan Clinical Oncology Group Study (JCOG1607, HERB TEA study). Jpn J Clin Oncol. 2021 51(9):1471-1474.
  4. Hara H, Uemura Y, Hayakawa K, Togano T, Asai Y, Matsunaga N, Terada M, Ohtsu H, Kitajima K, Shimizu Y, Sato L, Ishikane M, Kinoshita-Iwamoto N, Shibata T, Kondo M, Izumi K, Sugiura W, Ohmagari N. Evaluation of the efficacy of anticoagulation therapy in reducing mortality in a nationwide cohort of hospitalized patients with coronavirus disease in Japan, International Journal of Infectious Disesases. 2021 112:111-116.
  5. Mizuno T, Yoshida T, Sunami K, Koyama T, Okita N, Kubo T, Sudo K, Shimoi T, Ueno H, Saito E, Katanoda K, Shibata T, Yonemori K, Okusaka T, Boku N, Ohe Y, Hiroshima Y, Ueno M, Kuboki Y, Doi T, Nakamura K, Kohno T, Yatabe Y, Yamamoto N. Study protocol for NCCH1908 (UPFRONT-trial): a prospective clinical trial to evaluate the feasibility and utility of comprehensive genomic profiling prior to the initial systemic treatment in advanced solid tumour patients. Jpn J Clin Oncol. 2021 51(12):1757-1760.
  6. Matsunaga N, Hayakawa K, Terada M, Ohtsu H, Asai Y, Tsuzuki S, Suzuki S, Toyoda A, Suzuki K, Endo M, Fujii N, Suzuki M, Saito S, Uemura Y, Shibata T, Kondo M, Izumi K, Terada-Hirashima J, Mikami A, Sugiura W, Ohmagari N. Clinical epidemiology of hospitalized patients with COVID-19 in Japan: Report of the COVID-19 REGISTRY JAPAN. Clinical Infectious Diseases 2021 73(11):e3677-e3689.
  7. Nishino K, Fujiwara Y, Ohe Y, Saito R, Miyauchi E, Kobayashi T, Nakai Y, Takahashi T, Shibata T, Hamaguchi T, Kikuchi K, Yamazaki N, Fukuda H, Nozawa K, Kiyohara Y. Results of the non-small cell lung cancer part of a phase III, open-label, randomized trial evaluating topical corticosteroid therapy for facial acneiform dermatitis induced by EGFR inhibitors: stepwise rank down from potent corticosteroid (FAEISS study, NCCH-1512). Supportive Care in Cancer. 2021 29(5):2327-2334.
  8. Tagawa T, Yamada M, Minagawa T, Sekiguchi M, Konda K, Tanaka H, Takamaru H, Sekiguchi M, Sakamoto T, Matsuda T, Kuchiba A, Yoshida H, Saito Y. Endoscopic characteristics influencing postpolypectomy bleeding in consecutive 1147 pedunculated colonic polyps: a multicenter retrospective study. Gastrointest Endosc. 2021 94(4):803-811.e6.
  9. Ishikawa M, Shibata T, Iwata T, Nishio S, Takada T, Suzuki S, Horie K, Kudaka W, Kagabu M, Tanikawa M, Kitagawa R, Takekuma M, Kobayashi H, Yaegashi N. A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Primary analysis. Gynecol Oncol. 2021 162(2):292-298.
  10. Fujimoto K, Arita H, Satomi K, Yamasaki K, Matsushita Y, Nakamura T, Miyakita Y, Umehara T, Kobayashi K, Tamura K, Tanaka S, Higuchi F, Okita Y, Kanemura Y, Fukai J, Sakamoto D, Uda T, Machida R, Kuchiba A, Maehara T, Nagane M, Nishikawa R, Suzuki H, Shibuya M, Komori T, Narita Y, Ichimura K. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma. Acta Neuropathol. 2021 142(2):323-338.
  11. Ochi E, Tsuji K, Narisawa T, ShimizuY, Kuchiba A, Suto A, Jimbo K, Takayama S, Ueno T, Sakurai N. Matsuoka YJ. Effect of home-based smartphone-supported high-intensity interval training on cardiorespiratory fitness in breast cancer survivors: a randomized controlled trial of the habit-B program. BMJ Supportive & Palliative Care. 2022 12(1):33-37.